
usd pm et
summari global develop market anim vaccin medicin diagnost livestock
produc veterinarian
price-to-earnings oper ep
risk assess reflect compani strong
posit global anim heath market
possess attract product divers geograph
reach risk rate also reflect strong growth
potenti see global pet ownership rate middl
class expand less develop market also less
expos research develop patent
reimburs risk face tradit human
pharmaceut firm posit factor
somewhat mitig potenti new restrict
antibiot food-produc anim consum
trend away tradit meat product
feb ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
lift price target
ep estim --
histor forward price-to-earnings averag due
rapid growth pet-rel sale
maintain ep estim
start ep vs
beat consensu revenu grew
yoy companion anim
total yoy lead way demand
growth pet medic think
companion healthi long-term growth
runway expect global pet ownership
keep rise middl class expand
emerg market livestock sale
total fell yoy howev think
segment long-term growth could limit
rapid uptak plant-bas meat
imit adjust ep grew yoy
see pace come slightli
without benefit last year
abaxi acquisit keep hold rate
current valuat alreadi reflect
strong market posit growth prospect
view /colin scarola
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview zoeti among top global competitor discoveri develop
manufactur market anim health medicin vaccin focu livestock
companion anim compani market divers rang product livestock speci cattl
beef dairi swine poultri sheep fish companion anim speci dog cat
hors chief product categori anti-infect vaccin parasiticid medic feed addit
pharmaceut product also offer diagnost devic anim health product
compani directli market product countri product sold anoth nation
non-direct channel sale account total emerg
market brazil china mexico account brazil largest intern market
sale account total
livestock farm anim product mainli cattl swine account total sale
compris item cattl swine poultri fish sheep select livestock product includ
ceftiofur draxxin antibiot cattl swine sheep bovishield improvac respisur rispov
vaccin cattl swine cydectin dectomax parasiticid cattl sheep
long-term macro driver livestock product includ growth global popul rise standard
live rise demand improv nutrit particularli anim protein
product companion pet primarili dog cat repres sale princip brand
includ clavamox covinia terramycin anti-infect vanguard vaccin revolution/stronghold
parasiticid growth busi driven econom develop relat increas
treatment companion anim advanc anim health medicin vaccin
beyond livestock companion anim product oper gener rema revenu
total busi like contract manufactur
corpor strategi compani may pursu acquisit technolog licens arrang
strateg allianc divestitur busi part overal strategi drive growth
leverag road global footprint zoeti strive provid custom innov product
servic also place great emphasi spawn extens diversifi product
portfolio line latter strategi compani pursu develop new vaccin
emerg infecti diseas anim spent million revenu
million revenu
juli complet acquisit abaxi inc california corpor focus
develop manufactur market diagnost instrument veterinari point-of-car servic
acquir outstand common share abaxi per share cash result
abaxi becom wholly-own subsidiari acquisit enhanc presenc grow
market veterinari diagnost acquisit date fair valu consider transfer
approxim billion paid primarili new debt billion well cash hand
competit landscap prior zoeti apart larg pharmaceut firm
compani still primarili compet anim health divis within larg pharmaceut firm
competitor includ merck anim health divis merial anim health divis sanofi
elanco former subsidiari public bayer anim health novarti anim health
estim largest player anim health market term revenu follow
financi trend sale risen billion billion repres
three-year compound annual growth rate adjust pre-tax incom per share risen
repres three-year compound-annual-growth-rate improv profit margin
primari driver growth earn per share outpac sale growth leverag
level modest view adjust oper earn cover interest expens
execut vice-president chief
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc octob technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth driven
slowdown novel drug approv
potenti new price regul
neg partial off-set upcom
favor period patent expir
also expect major gener maker continu
struggl lower cost foreign competit
keep pressur profit margin
banner year new brand
drug fda see slowdown
total novel drug
approv fda
signific surg compar approv
new brand help drive
ebitda growth sub-industri
versu averag
new drug launch appear
slow howev
approv year august
period also observ
yoy declin spend
like portend effort maintain margin
sluggish revenu growth year ahead
pharmaceut also face increas risk
new drug price rule view
accord wall street journal studi
govern health system develop
countri like england norway canada
often pay less major drug
poll indic american feel drug
cost unreason believ
dynam increas pressur drug
maker curtail price hike politician
enact polici lower drug cost
voter accordingli sever new propos
lower drug price emerg side
isl recent month trump
administr announc explor base
medicar drug price intern index
hous democrat introduc bill
would allow medicar directli negoti
price drug maker senat
republican propos lower
out-of-pocket maximum medicar drug
plan shift cost burden
drug maker none propos
current enough support becom law
view see polit parti
increas focu control drug cost
signific risk weigh outlook
sub-industri
balanc neg factor face
brand drug maker expect
upcom favor period patent
expir typic biggest
revenu headwind base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
major gener maker neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
estim india-bas produc oper
averag gross margin
versu top western gener
foreign firm
drop broader composit
year-to-d septemb
pharmaceut index
gain
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target ep estim
long-term averag forward price-to-earnings expect recent acquisit expans
companion anim segment fuel above-averag growth ep
vs ahead consensu maintain ep estim lower
start sale rose yoy led
robust growth companion segment total revenue grew sale
yoy aid acquisit ca-bas abaxi juli well
robust growth intern companion sale believ intern
companion sale remain excel growth opportun
companion lead growth livestock segment tot revenue livestock
sale growth deceler yoy high single-digit
weaker cattl demand like market posit growth outlook high
valuat keep us neutral share /colin scarola
rais target price above-p
forward ep estim above-p growth ep
vs ahead estim rais ep
estim ep estim
sale rose believ gain market share strong demand
new parasiticid vaccin dermatolog product sale
rose companion anim product sale livestock product
sale sale rose companion anim product
livestock modest soft sale cattl product partial off-set
strong sale poultri swine product complet acquisit
abaxi develop veterinari diagnost instrument juli see
veterinari diagnost one fastest grow area anim health
analyst research note compani news
pm et cfra keep hold opinion share zoeti inc
lift price target ep estim
-- histor forward price-to-earnings averag due rapid growth
pet-rel sale maintain ep estim start
ep vs beat consensu revenu
grew yoy companion anim total yoy lead
way demand growth pet medic think companion healthi
long-term growth runway expect global pet ownership keep rise
middl class expand emerg market livestock sale total fell
yoy howev think segment long-term growth could limit
rapid uptak plant-bas meat imit adjust ep grew yoy
see pace come slightli without benefit
last year abaxi acquisit keep hold rate current
valuat alreadi reflect strong market posit growth prospect
view /colin scarola
et cfra keep hold opinion share zoeti inc
lift target ep estim
histor forward price-to-earnings averag due rapid growth pet-rel sale
rais ep estim
ep vs beat consensu sale rose yoy
led companion anim total sale grew yoy aid
abaxi acquisit juli livestock sale continu
declin howev sale drop yoy drop yoy
cattl swine product poultri fish saw sale rise strong demand
though reflect long-term trend toward healthier eat view
adjust pre-tax incom per share grew yoy slightli slower
revenu jump sg restructur expens compress margin yoy
expect margin improv cost synergi abaxi
realiz see alreadi reflect valuat think
near fair valu /colin scarola
pm et cfra keep hold opinion share zoeti inc
lift target price ep estim --
histor forward price-to-earnings averag due rapid growth pet-rel sale
ep vs beat consensu maintain
ep estim revenu rose yoy led growth companion
anim sale aid acquisit abaxi juli
livestock sale fell yoy howev driven weaker demand
 particularli cattl swine product convers chicken
fish sale increas think reflect trend toward healthier eat
despit revenu growth adjust pre-tax incom fell yoy oper
expens continu grow faster sale expect margin improv later
howev integr abaxi strong market
posit long-term growth outlook view especi companion
think alreadi fulli reflect premium valuat /colin
et cfra keep hold opinion share zoeti inc
lift target ep estim -- line
histor forward price-to-earnings averag ep vs beat
consensu rais ep estim keep
sale rose yoy led growth companion anim
sale aid acquisit abaxi juli maker
veterinari diagnost livestock sale fell yoy howev driven
softer demand cattl custom despit materi revenu growth
quarter estim adjust pre-tax incom per share fell yoy oper
expens grew materi faster sale pre-tax margin declin
six percentag point expect margin improv compani
progress abaxi integr strong market
posit long-term growth outlook view especi companion
premium valuat peer keep us neutral share /colin
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
